Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study

dc.contributor.authorScioscia, Giulia
dc.contributor.authorAmaro, Rosanel
dc.contributor.authorAlcaraz Serrano, Victoria
dc.contributor.authorGabarrús, Albert
dc.contributor.authorOscanoa, Patricia
dc.contributor.authorFernández Barat, Laia
dc.contributor.authorMenéndez, Rosario
dc.contributor.authorMéndez, Raúl
dc.contributor.authorFoschino Bárbaro, María Pía
dc.contributor.authorTorres Martí, Antoni
dc.date.accessioned2021-04-09T13:24:18Z
dc.date.available2021-04-09T13:24:18Z
dc.date.issued2019-11-12
dc.date.updated2021-04-09T13:24:19Z
dc.description.abstractBackground: Bronchiectasis exacerbations are often treated with prolonged antibiotic use, even though there is limited evidence for this approach. We therefore aimed to investigate the baseline clinical and microbiological findings associated with long courses of antibiotic treatment in exacerbated bronchiectasis patients. Methods: This was a bi-centric prospective observational study of bronchiectasis exacerbated adults. We compared groups receiving short (≤14 days) and long (15-21 days) courses of antibiotic treatment. Results: We enrolled 191 patients (mean age 72 (63, 79) years; 108 (56.5%) females), of whom 132 (69%) and 59 (31%) received short and long courses of antibiotics, respectively. Multivariable logistic regression of the baseline variables showed that long-term oxygen therapy (LTOT), moderate-severe exacerbations, and microbiological isolation of Pseudomonas aeruginosa were associated with long courses of antibiotic therapy. When we excluded patients with a diagnosis of community-acquired pneumonia (n = 49), in the model we found that an etiology of P. aeruginosa remained as factor associated with longer antibiotic treatment, with a moderate and a severe FACED score and the presence of arrhythmia as comorbidity at baseline. Conclusions: Decisions about the duration of antibiotic therapy should be guided by clinical and microbiological assessments of patients with infective exacerbations.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec698288
dc.identifier.issn2077-0383
dc.identifier.pmid31726739
dc.identifier.urihttps://hdl.handle.net/2445/176143
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm8111950
dc.relation.ispartofJournal of Clinical Medicine, 2019, vol. 8, num. 11, p. 1950
dc.relation.urihttps://doi.org/10.3390/jcm8111950
dc.rightscc-by (c) Scioscia, Giulia et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalalties bronquials
dc.subject.classificationAntibiòtics
dc.subject.otherBronchial diseases
dc.subject.otherAntibiotics
dc.titleClinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
698288.pdf
Mida:
714.19 KB
Format:
Adobe Portable Document Format